For cardiovascular irAEs, older patients show a clear trend of increased toxicity risk.
← all excerpts
Immune-related adverse events in older adults receiving immune checkpoint inhibitors: a comprehensive analysis of the Food and Drug Administration Adverse Event Reporting System.
1
—
—